TITLE:
Efficacy and Safety of Viusid and Asbrip in Hospitalized Patients with Mild and Moderate COVID-19: A Randomized Controlled Trial
AUTHORS:
Petar Petrov, Aleksandar Mihaylov, Maria Shopova, Maria Boncheva, David Marquez
KEYWORDS:
Immunomodulator, COVID-19, Hospitalization, Recovery, Antioxidant
JOURNAL NAME:
Advances in Infectious Diseases,
Vol.11 No.2,
May
19,
2021
ABSTRACT: Background: The aim of this study was to test Viusid and Asbrip as adjuvants to the standard treatment of patients with COVID-19 disease which could favor the recovery of the patients and reduce the hospitalization days. Design: This is a randomized, open-label, controlled trial to determine the efficacy and safety of Viusid and Asbrip in hospitalized patients with mild to moderate symptoms of COVID-19. Material and Methods: A total of 60 patients with proven COVID-19 disease by PCR test were randomized in a 2:1 ratio. In the active group 40 patients received oral doses of Viusid (30 ml TID) and Asbrip (10 ml TID) plus standard treatment. The control group consisted of 20 patients receiving only standard treatment. The trial began with hospitalization, followed by home treatment for a total of 21 days. Four symptoms were followed: fever, dyspnea, cough and fatigue, assessed by score 0 - 3: 0 = well, 1 = mild, 2 = moderate, 3 = severe, with total sum, Composite Symptom Score (CSS) from 0 to 12. Results: The 21 days diagram of CSS shows statistically better results of Viusid-Asbrip group vs. Control group from day 4 to day 21. Time to semi-recovery in days, assessed by 50% of CSS, is better in Viusid-Asbrip group vs. Control group (6.07 ± 2.77 vs. 8.35 ± 2.94, p = 0.02). Time to recovery in days respectively is (14.05 ± 4.15 vs. 19.25 ± 2.12, p = 0.0001). And Hospitalization days are (9.05 ± 2.58 vs. 12.75 ± 4.44, p = 0.0003). Conclusion: This trial shows that adding of Viusid & Asbrip to the treatment of COVID-19 can contribute to faster recovery of the patients, decreasing of the hospital stay and milder course of the disease.